Country: Canada
Language: English
Source: Health Canada
VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE)
PHARMASCIENCE INC
J05AB11
VALACICLOVIR
500MG
TABLET
VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500MG
ORAL
100
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0128626001; AHFS:
APPROVED
2008-05-15
_pms-VALACYCLOVIR (Valacyclovir Tablets) page 1 of 39 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-VALACYCLOVIR Valacyclovir tablets Tablets, 500 mg and 1000 mg (as valacyclovir hydrochloride), oral House Standard Antiviral Agent PHARMASCIENCE INC. Date of Initial Authorization: 6111 Royalmount Ave., Suite 100 MAY 15, 2008 Montréal, Québec H4P 2T4 Date of Revision: MAY 10, 2023 www.pharmascience.com Submission Control Number: 270106 _pms-VALACYCLOVIR (Valacyclovir Tablets) page 2 of 39 _ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................................................. 2 TABLE OF CONTENTS ................................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................................ 4 1 INDICATIONS ............................................................................................................................... 4 1.1 Pediatrics ................................................................................................................................... 4 1.2 Geriatrics ................................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................................. 4 4.1 Dosing Considerations ............................................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ................................................................. Read the complete document